Myelodysplastic syndrome

Disease ID:1201
Name:Myelodysplastic syndrome
Associated with:0 target
2 immuno-relevant ligands
Description
A bone marrow cancer characterized by insufficient production of white blood cells, red blood cells and platelets.
Database Links
Disease Ontology: DOID:0050908
OMIM: 614286

Targets

No target related data available for Myelodysplastic syndrome

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
azacitidine
Immuno Disease Comments: Approved drug for myelodysplastic syndrome.
Clinical Use: Antineoplastic agent used in the treatment of myelodysplastic syndrome.
(an HDAC inhibitor) is being evaluated in a Phase II clinical trial alongside azacitidine (which has an epigenetic priming effect [1]) prior to check-point immunotherapy with in patients with recurrent metastatic non-small cell lung cancer- see NCT01928576. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target(s) to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
talmapimod
Immuno Disease Comments: Phase 2 candidate for myelodysplastic syndrome, but has not progressed further.
Clinical Use: Talmapimod has been assessed in several completed Phase II clinical trials for myelodysplastic syndromes and active rheumatoid arthritis. Click here for ClinicalTrials.org's full list of completed talmapimod (SCIO-469) trials. There are no active trials registered with ClinicalTrials.org (Nov 2014). | View clinical data

References

Show »

1. Dear AE. (2016) Epigenetic Modulators and the New Immunotherapies. N. Engl. J. Med., 374 (7): 684-6. [PMID:26886527]